Katie L Flanagan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3149637/publications.pdf Version: 2024-02-01



Κάτις Ι. Ει ανιάς ανι

#	Article	IF	CITATIONS
1	Clinical features and mechanistic insights into drug repurposing for combating COVID-19. International Journal of Biochemistry and Cell Biology, 2022, 142, 106114.	1.2	12
2	Hepatitis B vaccine co-administration influences the heterologous effects of neonatal BCG vaccination in a sex-differential manner. Vaccine, 2022, 40, 1334-1341.	1.7	3
3	Leveraging Beneficial Off-Target Effects of Live-Attenuated Rotavirus Vaccines. Vaccines, 2022, 10, 418.	2.1	4
4	RSV Prevention in All Infants: Which Is the Most Preferable Strategy?. Frontiers in Immunology, 2022, 13, 880368.	2.2	50
5	Cutting Edge: SARS-CoV-2 Infection Induces Robust Germinal Center Activity in the Human Tonsil. Journal of Immunology, 2022, , ji2101199.	0.4	6
6	SARS-CoV-2-specific TÂcell memory with common TCR $\hat{1}\pm\hat{1}^2$ motifs is established in unvaccinated children who seroconvert after infection. Immunity, 2022, 55, 1299-1315.e4.	6.6	23
7	Key steps in our journey to a COVIDâ€19 vaccine program. Medical Journal of Australia, 2021, 214, 249.	0.8	4
8	Potential Impact of Human Cytomegalovirus Infection on Immunity to Ovarian Tumours and Cancer Progression. Biomedicines, 2021, 9, 351.	1.4	15
9	Systems serology detects functionally distinct coronavirus antibody features in children and elderly. Nature Communications, 2021, 12, 2037.	5.8	125
10	CD8+ T cell landscape in Indigenous and non-Indigenous people restricted by influenza mortality-associated HLA-A*24:02 allomorph. Nature Communications, 2021, 12, 2931.	5.8	20
11	CD8+ TÂcells specific for an immunodominant SARS-CoV-2 nucleocapsid epitope display high naive precursor frequency and TCR promiscuity. Immunity, 2021, 54, 1066-1082.e5.	6.6	106
12	Neonatal Bacille Calmette-Guérin Vaccination and Infections in the First Year of Life: The MIS BAIR Randomized Controlled Trial. Journal of Infectious Diseases, 2021, 224, 1115-1127.	1.9	13
13	Adaptive Immunity and the Risk of Autoreactivity in COVID-19. International Journal of Molecular Sciences, 2021, 22, 8965.	1.8	35
14	Prevention of infant eczema by neonatal bacille Calmetteâ€Guérin vaccination: The MIS BAIR randomized controlled trial. Allergy: European Journal of Allergy and Clinical Immunology, 2021, , .	2.7	10
15	Coadministration of Anti-Viral Monoclonal Antibodies With Routine Pediatric Vaccines and Implications for Nirsevimab Use: A White Paper. Frontiers in Immunology, 2021, 12, 708939.	2.2	8
16	SARS-CoV-2 Vaccines: Where Are We Now?. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 3535-3543.	2.0	36
17	COVID-19 vaccines - are we there yet?. Australian Prescriber, 2021, 44, 19-25.	0.5	15
18	Robust and prototypical immune responses toward influenza vaccines in the high-risk group of Indigenous Australians. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	4

#	Article	IF	CITATIONS
19	Global Perspectives on Immunization Against SARS-CoV-2 During Pregnancy and Priorities for Future Research: An International Consensus Paper From the World Association of Infectious Diseases and Immunological Disorders. Frontiers in Immunology, 2021, 12, 808064.	2.2	13
20	How lifestyle factors and their associated pathogenetic mechanisms impact psoriasis. Clinical Nutrition, 2020, 39, 1026-1040.	2.3	24
21	Biological sex influences antibody responses to routine vaccinations in the first year of life. Acta Paediatrica, International Journal of Paediatrics, 2020, 109, 147-157.	0.7	7
22	Influenzaâ€specific IgG1 ⁺ memory B ell numbers increase upon booster vaccination in healthy adults but not in patients with predominantly antibody deficiency. Clinical and Translational Immunology, 2020, 9, e1199.	1.7	12
23	Microbial exposure drives polyclonal expansion of innate γδT cells immediately after birth. Proceedings of the United States of America, 2020, 117, 18649-18660.	3.3	45
24	The Australasian COVID-19 Trial (ASCOT) to assess clinical outcomes in hospitalised patients with SARS-CoV-2 infection (COVID-19) treated with lopinavir/ritonavir and/or hydroxychloroquine compared to standard of care: A structured summary of a study protocol for a randomised controlled trial. Trials, 2020, 21, 646.	0.7	11
25	Coronavirus Disease-19: An Interim Evidence Synthesis of the World Association for Infectious Diseases and Immunological Disorders (Waidid). Frontiers in Medicine, 2020, 7, 572485.	1.2	15
26	Immune responses to SARS-CoV-2 in three children of parents with symptomatic COVID-19. Nature Communications, 2020, 11, 5703.	5.8	90
27	Limited Impact of Human Cytomegalovirus Infection in African Infants on Vaccine-Specific Responses Following Diphtheria-Tetanus-Pertussis and Measles Vaccination. Frontiers in Immunology, 2020, 11, 1083.	2.2	6
28	Progress and Pitfalls in the Quest for Effective SARS-CoV-2 (COVID-19) Vaccines. Frontiers in Immunology, 2020, 11, 579250.	2.2	72
29	Sex-Differential Impact of Human Cytomegalovirus Infection on In Vitro Reactivity to Toll-Like Receptor 2, 4 and 7/8 Stimulation in Gambian Infants. Vaccines, 2020, 8, 407.	2.1	0
30	Suboptimal SARS-CoV-2â^'specific CD8 ⁺ T cell response associated with the prominent HLA-A*02:01 phenotype. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 24384-24391.	3.3	168
31	A population of CD4 hi CD38 hi T cells correlates with disease severity in patients with acute malaria. Clinical and Translational Immunology, 2020, 9, e1209.	1.7	3
32	The non-specific and sex-differential effects of vaccines. Nature Reviews Immunology, 2020, 20, 464-470.	10.6	87
33	Global Perspectives on Immunization During Pregnancy and Priorities for Future Research and Development: An International Consensus Statement. Frontiers in Immunology, 2020, 11, 1282.	2.2	68
34	Human Mucosal-Associated Invariant T Cells in Older Individuals Display Expanded TCRαβ Clonotypes with Potent Antimicrobial Responses. Journal of Immunology, 2020, 204, 1119-1133.	0.4	36
35	Neonatal BCG Vaccination Reduces Interferon-Î ³ Responsiveness to Heterologous Pathogens in Infants From a Randomized Controlled Trial. Journal of Infectious Diseases, 2020, 221, 1999-2009.	1.9	24
36	New therapeutic targets for the prevention of infectious acute exacerbations of COPD: role of epithelial adhesion molecules and inflammatory pathways. Clinical Science, 2019, 133, 1663-1703.	1.8	41

#	Article	IF	CITATIONS
37	Pertussis Prevention: Reasons for Resurgence, and Differences in the Current Acellular Pertussis Vaccines. Frontiers in Immunology, 2019, 10, 1344.	2.2	105
38	The influence of neonatal Bacille Calmette-Guérin (BCG) immunisation on heterologous vaccine responses in infants. Vaccine, 2019, 37, 3735-3744.	1.7	31
39	Will dual Japanese encephalitis and measles-rubella vaccination hinder measles and rubella eradication?. Lancet Infectious Diseases, The, 2019, 19, 344-345.	4.6	1
40	Malaria vaccines in the eradication era: current status and future perspectives. Expert Review of Vaccines, 2019, 18, 133-151.	2.0	30
41	The microgenderome revealed: sex differences in bidirectional interactions between the microbiota, hormones, immunity and disease susceptibility. Seminars in Immunopathology, 2019, 41, 265-275.	2.8	160
42	Study protocol for the Melbourne Infant Study: BCG for Allergy and Infection Reduction (MIS BAIR), a randomised controlled trial to determine the non-specific effects of neonatal BCG vaccination in a low-mortality setting. BMJ Open, 2019, 9, e032844.	0.8	9
43	Neonatal BCG Vaccination Influences Cytokine Responses to Toll-like Receptor Ligands and Heterologous Antigens. Journal of Infectious Diseases, 2018, 217, 1798-1808.	1.9	75
44	Effect of sex on vaccination outcomes: important but frequently overlooked. Current Opinion in Pharmacology, 2018, 41, 122-127.	1.7	13
45	Viral Vector Malaria Vaccines Induce High-Level T Cell and Antibody Responses in West African Children and Infants. Molecular Therapy, 2017, 25, 547-559.	3.7	34
46	The Economics of Malaria Vaccine Development. Trends in Parasitology, 2017, 33, 154-156.	1.5	3
47	Measles Vaccination Is Effective at Under Nine Months of Age, and Provides Nonspecific Immunological Benefits. Journal of Infectious Diseases, 2017, 215, 1177-1178.	1.9	2
48	Sex and Gender Differences in the Outcomes of Vaccination over the Life Course. Annual Review of Cell and Developmental Biology, 2017, 33, 577-599.	4.0	355
49	Long-term sex-differential effects of neonatal vitamin A supplementation on <i>in vitro</i> cytokine responses. British Journal of Nutrition, 2017, 118, 942-948.	1.2	3
50	Sex-differential heterologous (non-specific) effects of vaccines: an emerging public health issue that needs to be understood and exploited. Expert Review of Vaccines, 2017, 16, 5-13.	2.0	24
51	Vaccination with Altered Peptide Ligands of a Plasmodium berghei Circumsporozoite Protein CD8 T-Cell Epitope: A Model to Generate T Cells Resistant to Immune Interference by Polymorphic Epitopes. Frontiers in Immunology, 2017, 8, 115.	2.2	1
52	Negative Correlation between Circulating CD4+FOXP3+CD127â^' Regulatory T Cells and Subsequent Antibody Responses to Infant Measles Vaccine but Not Diphtheria–Tetanus–Pertussis Vaccine Implies a Regulatory Role. Frontiers in Immunology, 2017, 8, 921.	2.2	13
53	Minimal Sex-Differential Modulation of Reactivity to Pathogens and Toll-Like Receptor Ligands following Infant Bacillus Calmette–Guérin Russia Vaccination. Frontiers in Immunology, 2017, 8, 1092.	2.2	9
54	Manipulating the microbiota to improve human health throughout life. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2017, 111, 379-381.	0.7	3

#	Article	IF	CITATIONS
55	Timing of routine infant vaccinations and risk of food allergy and eczema at one year of age. Allergy: European Journal of Allergy and Clinical Immunology, 2016, 71, 541-549.	2.7	28
56	Sex-Differential Non-Vaccine-Specific Immunological Effects of Diphtheria-Tetanus-Pertussis and Measles Vaccination. Clinical Infectious Diseases, 2016, 63, ciw492.	2.9	31
57	Sex differences in immune responses. Nature Reviews Immunology, 2016, 16, 626-638.	10.6	3,615
58	The global challenge and future strategies for keeping the world's aging population healthy by vaccination. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2016, 110, 427-431.	0.7	4
59	Safety and Immunogenicity of ChAd63 and MVA ME-TRAP in West African Children and Infants. Molecular Therapy, 2016, 24, 1470-1477.	3.7	52
60	Polymorphism in liver-stage malaria vaccine candidate proteins: immune evasion and implications for vaccine design. Expert Review of Vaccines, 2016, 15, 389-399.	2.0	15
61	Whole blood gene expression profiling of neonates with confirmed bacterial sepsis. Genomics Data, 2015, 3, 41-48.	1.3	32
62	Early Virological and Immunological Events in Asymptomatic Epstein-Barr Virus Infection in African Children. PLoS Pathogens, 2015, 11, e1004746.	2.1	64
63	Heterologous and sex differential effects of administering vitamin A supplementation with vaccines. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2015, 109, 36-45.	0.7	12
64	Vaccines have sex differential non-targeted heterologous effects: a new dawn in vaccine research. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2015, 109, 1-2.	0.7	5
65	Heterologous Immunological Effects of Early BCG Vaccination in Low-Birth-Weight Infants in Guinea-Bissau: A Randomized-controlled Trial. Journal of Infectious Diseases, 2015, 211, 956-967.	1.9	171
66	Haematological and biochemical reference values of <scp>G</scp> ambian infants. Tropical Medicine and International Health, 2014, 19, 275-283.	1.0	11
67	Targeting regulatory T cells to improve vaccine immunogenicity in early life. Frontiers in Microbiology, 2014, 5, 477.	1.5	74
68	Protection Versus Pathology in Aviremic and High Viral Load HIV-2 Infection—The Pivotal Role of Immune Activation and T-cell Kinetics. Journal of Infectious Diseases, 2014, 210, 752-761.	1.9	15
69	Identification of a human neonatal immune-metabolic network associated with bacterial infection. Nature Communications, 2014, 5, 4649.	5.8	112
70	Factors affecting immunogenicity of BCG in infants, a study in Malawi, The Gambia and the UK. BMC Infectious Diseases, 2014, 14, 184.	1.3	27
71	A double blind randomized controlled trial in neonates to determine the effect of vitamin A supplementation on immune responses: The Gambia protocol. BMC Pediatrics, 2014, 14, 92.	0.7	11
72	Sexual dimorphism in biomedical research: a call to analyse by sex. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2014, 108, 385-387.	0.7	33

#	Article	IF	CITATIONS
73	Translating the Immunogenicity of Prime-boost Immunization With ChAd63 and MVA ME-TRAP From Malaria Naive to Malaria-endemic Populations. Molecular Therapy, 2014, 22, 1992-2003.	3.7	49
74	Randomized trial: The effect of oral polio vaccine at birth on polio antibody titers at 6weeks and 6months of age. Trials in Vaccinology, 2014, 3, 33-39.	1.2	4
75	Heterologous ("Nonspecific") and Sex-Differential Effects of Vaccines: Epidemiology, Clinical Trials, and Emerging Immunologic Mechanisms. Clinical Infectious Diseases, 2013, 57, 283-289.	2.9	97
76	Impaired Th1 immunity in ovarian cancer patients is mediated by TNFR2+ Tregs within the tumor microenvironment. Clinical Immunology, 2013, 149, 97-110.	1.4	108
77	Comparing HIVâ€1 and HIVâ€2 infection: Lessons for viral immunopathogenesis. Reviews in Medical Virology, 2013, 23, 221-240.	3.9	172
78	Safety and Immunogenicity of Heterologous Prime-Boost Immunisation with Plasmodium falciparum Malaria Candidate Vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in Healthy Gambian and Kenyan Adults. PLoS ONE, 2013, 8, e57726.	1.1	64
79	A Phase I Randomized Clinical Trial of Candidate Human Immunodeficiency Virus type 1 Vaccine MVA.HIVA Administered to Gambian Infants. PLoS ONE, 2013, 8, e78289.	1.1	17
80	T-cell immunity to Kaposi sarcoma–associated herpesvirus: recognition of primary effusion lymphoma by LANA-specific CD4+ T cells. Blood, 2012, 119, 2083-2092.	0.6	29
81	Immunological impact of an additional early measles vaccine in Gambian children: Responses to a boost at 3 years. Vaccine, 2012, 30, 2543-2550.	1.7	30
82	Are Plasma Biomarkers of Immune Activation Predictive of HIV Progression: A Longitudinal Comparison and Analyses in HIV-1 and HIV-2 Infections?. PLoS ONE, 2012, 7, e44411.	1.1	21
83	Placental malaria is associated with attenuated CD4 T-cell responses to tuberculin PPD 12 months after BCG vaccination. BMC Infectious Diseases, 2012, 12, 6.	1.3	17
84	Age-Dependent Maturation of Toll-Like Receptor-Mediated Cytokine Responses in Gambian Infants. PLoS ONE, 2011, 6, e18185.	1.1	109
85	Randomized Trials to Study the Nonspecific Effects of Vaccines in Children in Low-Income Countries. Pediatric Infectious Disease Journal, 2010, 29, 457-461.	1.1	34
86	The effect of placental malaria infection on cord blood and maternal immunoregulatory responses at birth. European Journal of Immunology, 2010, 40, 1062-1072.	1.6	47
87	The Tuberculin Skin Test (TST) Is Affected by Recent BCG Vaccination but Not by Exposure to Non-Tuberculosis Mycobacteria (NTM) during Early Life. PLoS ONE, 2010, 5, e12287.	1.1	44
88	The challenge of assessing infant vaccine responses in resource-poor settings. Expert Review of Vaccines, 2010, 9, 665-674.	2.0	18
89	Delaying Bacillus Calmette-Guérin Vaccination from Birth to 4 1/2 Months of Age Reduces Postvaccination Th1 and IL-17 Responses but Leads to Comparable Mycobacterial Responses at 9 Months of Age. Journal of Immunology, 2010, 185, 2620-2628.	0.4	84
90	Placental Malaria is associated with reduced early life weight development of affected children independent of low birth weight. Malaria Journal, 2010, 9, 16.	0.8	25

#	Article	IF	CITATIONS
91	Epidemiological studies of the †nonâ€specific effects' of vaccines: I – data collection in observational studies. Tropical Medicine and International Health, 2009, 14, 969-976.	1.0	25
92	Correlation of Memory T Cell Responses against TRAP with Protection from Clinical Malaria, and CD4+ CD25high T Cells with Susceptibility in Kenyans. PLoS ONE, 2008, 3, e2027.	1.1	82
93	Rapid Molecular Detection of Rifampicin Resistance Facilitates Early Diagnosis and Treatment of Multi-Drug Resistant Tuberculosis: Case Control Study. PLoS ONE, 2008, 3, e3173.	1.1	42
94	Cytomegalovirus ileitis associated with goblet cell carcinoid tumour of the appendix. Journal of Infection, 2007, 54, e153-e156.	1.7	5
95	Predicting memory: a prospective readout for malaria vaccines?. Trends in Parasitology, 2007, 23, 341-343.	1.5	6
96	Risk Factors for and Clinical Outcome of Congenital Cytomegalovirus Infection in a Peri-Urban West-African Birth Cohort. PLoS ONE, 2007, 2, e492.	1.1	67
97	Quinine levels revisited: the value of routine drug level monitoring for those on parenteral therapy. Acta Tropica, 2006, 97, 233-237.	0.9	16
98	DimorphicPlasmodium falciparum merozoite surface protein-1 epitopes turn off memory T cells and interfere with T cell priming. European Journal of Immunology, 2006, 36, 1168-1178.	1.6	23
99	CELLULAR REACTIVITY TO THE P. FALCIPARUM PROTEIN TRAP IN ADULT KENYANS: NOVEL EPITOPES, COMPLEX CYTOKINE PATTERNS, AND THE IMPACT OF NATURAL ANTIGENIC VARIATION. American Journal of Tropical Medicine and Hygiene, 2006, 74, 367-375.	0.6	22
100	IMPORTED PLASMODIUM FALCIPARUM MALARIA: ARE PATIENTS ORIGINATING FROM DISEASE-ENDEMIC AREAS LESS LIKELY TO DEVELOP SEVERE DISEASE? A PROSPECTIVE, OBSERVATIONAL STUDY. American Journal of Tropical Medicine and Hygiene, 2006, 75, 1195-1199.	0.6	34
101	Cellular reactivity to the p. Falciparum protein trap in adult kenyans: novel epitopes, complex cytokine patterns, and the impact of natural antigenic variation. American Journal of Tropical Medicine and Hygiene, 2006, 74, 367-75.	0.6	11
102	Imported Plasmodium falciparum malaria: are patients originating from disease-endemic areas less likely to develop severe disease? A prospective, observational study. American Journal of Tropical Medicine and Hygiene, 2006, 75, 1195-9.	0.6	15
103	Direct processing and presentation of antigen from malaria sporozoites by professional antigenâ€presenting cells in the induction of CD8 + Tâ€cell responses. Immunology and Cell Biology, 2005, 83, 307-312.	1.0	49
104	Pneumococcal meningitis and etanercept—chance or association?. Journal of Infection, 2005, 51, E49-E51.	1.7	16
105	Cellular immunity induced by the recombinant Plasmodium falciparum malaria vaccine, RTS,S/AS02, in semi-immune adults in The Gambia. Clinical and Experimental Immunology, 2004, 135, 286-293.	1.1	69
106	Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nature Medicine, 2003, 9, 729-735.	15.2	536
107	Postmalaria Neurological Syndrome: Two Cases from The Gambia. Clinical Infectious Diseases, 2003, 36, e29-e31.	2.9	20
108	EX VIVO INTERFERON-GAMMA IMMUNE RESPONSE TO THROMBOSPONDIN-RELATED ADHESIVE PROTEIN IN COASTAL KENYANS: LONGEVITY AND RISK OF PLASMODIUM FALCIPARUM INFECTION. American Journal of Tropical Medicine and Hygiene, 2003, 68, 421-430.	0.6	34

#	Article	IF	CITATIONS
109	Ex vivo interferon-gamma immune response to thrombospondin-related adhesive protein in coastal Kenyans: longevity and risk of Plasmodium falciparum infection. American Journal of Tropical Medicine and Hygiene, 2003, 68, 421-30.	0.6	23
110	Induction of T Helper Type 1 and 2 Responses to 19-Kilodalton Merozoite Surface Protein 1 in Vaccinated Healthy Volunteers and Adults Naturally Exposed to Malaria. Infection and Immunity, 2002, 70, 1417-1421.	1.0	35
111	Naturally Exposed Populations Differ in Their T1 and T2 Responses to the Circumsporozoite Protein of Plasmodium falciparum. Infection and Immunity, 2002, 70, 1468-1474.	1.0	14
112	Unique T Cell Effector Functions Elicited byPlasmodium falciparumEpitopes in Malaria-Exposed Africans Tested by Three T Cell Assays. Journal of Immunology, 2001, 167, 4729-4737.	0.4	57
113	Identification of frequently recognized dimorphic T-cell epitopes in plasmodium falciparum merozoite surface protein-1 in West and East Africans: lack of correlation of immune recognition and allelic prevalence American Journal of Tropical Medicine and Hygiene, 2001, 64, 194-203.	0.6	25
114	Altered peptide ligands narrow the repertoire of cellular immune responses by interfering with T-cell priming. Nature Medicine, 1999, 5, 565-571.	15.2	96
115	Broadly distributed T cell reactivity, with no immunodominant loci, to the pre-erythrocytic antigen thrombospondin-related adhesive protein ofPlasmodium falciparum in West Africans. European Journal of Immunology, 1999, 29, 1943-1954.	1.6	47
116	Potent Induction of Focused Th1â€Type Cellular and Humoral Immune Responses by RTS,S/SBAS2, a RecombinantPlasmodium falciparumMalaria Vaccine. Journal of Infectious Diseases, 1999, 180, 1656-1664.	1.9	148
117	Interleukin 10–Mediated Immunosuppression by a Variant CD4 T Cell Epitope of Plasmodium falciparum. Immunity, 1999, 10, 651-660.	6.6	114
118	Disseminated Infection Due to <i>Bipolaris australiensis</i> in a Young Immunocompetent Man: Case Report and Review. Clinical Infectious Diseases, 1997, 25, 311-313.	2.9	36
119	Robust and Prototypical Immune Responses Towards Influenza Vaccines in the High-Risk Group of Indigenous Australians. SSRN Electronic Journal, 0, , .	0.4	0
120	High Precursor Frequency and Promiscuity in Î [^] Î ² T Cell Receptor Pairing Underpin CD8+ T-Cell Responses to an Immunodominant SARS-CoV-2 Nucleocapsid Epitope. SSRN Electronic Journal, 0, , .	0.4	0